Aspira Women's Health Inc. · OTC:AWHL
Aspira Women's Health — Investor Presentation (January 2025)
26 slides from Aspira Women's Health's investor presentation, Jan 13, 2025
Slide 1: Investor Presentation January 2025
Investor Presentation January 2025 Nasdaq: AWH Non-Invasive, Breakthrough Tests for the Identification of Gynecologic Diseases
Slide 2: Safe Harbor
Safe Harbor 7 This presentation contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. These forward-looking statements include,
Slide 3: Company Highlights
Company Highlights Transforming Gynecologic Care Through Al-Enabled Diagnostics We are revolutionizing women’s health through innovative testing options, leveraging a data-driven approach to empower patients and healthcare providers in achieving optimal gynecologic care. Advancing Women’s Health Sta
Slide 4: An Experienced Women's Health Executive Team
An Experienced Women’s Health Executive Team > ¥.¥ id Sandra Milligan, MD, JD James O'Brien, CPA, MBA Michael Buhle Interim Chief Exec e Chief Financial Officer Senior Advisor “* ORGANON FARON me 5 eesti € MERCK Allergan Genentech pyc ‘lh AMGEN Bee, | = biog magene
Slide 5: Aspira Women's Health Investment Highlights
Aspira Women’s Health Investment Highlights Revenue Generating Company Efficient Growth ARPA-H Award Innovative Products Large TAM Market Access & Reimbursement Experienced Management Revenue generating commercial diagnostics company with year-over-year volume growth since 2020 Strategic commercial
Slide 6: >$1B Annual Revenue Potential from Current and Near-Term Products
>$1B Annual Revenue Potential from Current and Near-Term Products CvaSuite™ Cv?” peer Qe Monitoring 200-400K patients Increases TAM to proceed tosurgery for 2.0-3.0M potential ~2.8M by including an adnexal mass tests annually patients with genetic annually and familial risk $35M- $55M $560M-$660M TB
Slide 7: Recent Developments: ARPA-H Award
Recent Developments: ARPA-H Award
Slide 8: A Historic Investment in Women's Health
A Historic Investment in Women’s Health THE WHITE HOUSE Gynecology Neurological Obstetrics FACT SHEET: Biden-Harris Administration Announces $110 Million in Awards from ARPA-H’s Sprint for Women’s Health to Accelerate New Discoveries and Innovation Pain Management Menopause Cardiovascular The Sprint
Slide 9: A Robust, Highly Competitive Process Led to Our Success
A Robust, Highly Competitive Process Led to Our Success « Women’s Health Sprint sought proposals across six categories of women’s health challenges to fund the work that companies/institutions need to accelerate development * 1,700+ submissions, representing 45 states and 34 countries, received from
Slide 10: Breakthrough Advancement: Blood Test Diagnosis of Endometriosis
Breakthrough Advancement: Blood Test Diagnosis of Endometriosis with Multivariate Al Analytics AWH will receive milestone payments based on achievement of certain milestones || Milestone Description Hi Initial Project Launch - COMPLETED | szom | R&D Scale Up to Meet Operational Needs Biomarker Disco
Slide 11: Commercial Products
Commercial Products
Slide 12: Historical Treatment Paradigm Leads to Negative Outcomes
Historical Treatment Paradigm Leads to Negative Outcomes * 1.2-1.5M women in the U.S. present with an adnexal mass each year, of which 200-400K will be referred for surgery. + Most of those surgeries result in a non-malignant diagnosis. + In the U.S., women with ovarian cancer will wait an average o
Slide 13: Historical Clinical Consideration for Women with an Adnexal Mass
Historical Clinical Consideration for Women with an Adnexal Mass Bespin ® Patient presents Physical exam is Complete Ultrasound finds a with vague inconclusive for workup 6cm mass. abdominal definitive diagnosis includes orders It is ruled bloating that is of ovarian cancer. for an indeterminate. re
Slide 14: Aspira's Ovarian Cancer Product Portfolio & In-Development Tests
Aspira’s Ovarian Cancer Product Portfolio & In-Development Tests CvaSuite” Cva? “ Ovawate H° CVaiintorm with Longitudinal Monitoring Feature Commercially Commercially Under available available Development for adnexal masses for indeterminate and for adnexal masses planned for surgery likely benign a
Slide 15: Financial Performance Snapshot
Financial Performance Snapshot Q3 2024 YoY Comparison Product Volume +4% Gross Margin +184bps 6,783 ta 032023 © -Q3 2024 932023 03.2024 Product Revenue +2% $2.3M EI a a 932023. Q3 2024 932023 -Q3.2024 Sales & Marketing +21% Balance Sheet Cash as of September 30, 2024: $2.1M* 2024 Operating cash util
Slide 16: OvaSuite Designed to Address a Significant Unmet Need in Gynecologic Care
CvaSuite” Designed to Address a Significant Unmet Need in Gynecologic Care U.S. Total Addressable Market (TAM) Patients/Year May 2024 CvawarcH Longitudinal Monitoring The number of patients who benefit from our tests has increased with each expansion of the OvaSuite portfolio. With the launch of the
Slide 17: OvaWatch | For Initial and Ongoing Assessment of Ovarian Cancer Risk
Ovawat,cH” | For Initial and Ongoing Assessment of Ovarian Cancer Risk OvaWatch is a non-invasive test intended for use in assessing the risk of ovarian cancer for women with adnexal masses that are likely benign or cannot be classified by initial clinical assessment (indeterminate) CvawatcH’ With i
Slide 18: Strong Evidence to Support OvaWatch for Adnexal Mass Management
Strong Evidence to Support OvaWatch for Adnexal Mass Management “Ovarian Cancer Surgical Consideration is Markedly Improved by the Neural Network Powered MIA3G Multivariate Index Assay” published in Frontiers in Medicine (May 2024) Use of OvaWatch may have significantly reduced surgical intervention
Slide 19: Ova1Plus | For Women with Adnexal Masses Planned for Surgery
Ova?™| For Women with Adnexal Masses Planned for Surgery Ovai1Plus is a proprietary reflex process Included in Guidelines for Adnexal at Mass Management ACOG The American College of Obstetricians and Gynecologists Ova‘ performs better than off-label use of CA-125 alone Ovarian malignancies Pee 59 %
Slide 20: OvaSuite | Market Access and Reimbursement
CvaSuite” | Market Access and Reimbursement We aim to make our OvaSuite of products available to all women C & Medicare $897ia a Medicaid On the fee schedule in 11 states Medicare Advantage BEG Carelirst , Anthem | Cigna m0 mae O) Yelitfeare Louisiana SHIGHMARK. | ger@ 2S | gy scr aR NAWallCare | uy
Slide 21: Development Pipeline
Development Pipeline
Slide 22: OVAinform | Breakthrough Assays for Identification of Ovarian Cancer
CyVaiintorm | Breakthrough Assays for Identification of Ovarian Cancer Aspira’s Advantages OVAinform Assay Features @%_ Existing protein-based FDA A promising new Al-enabled blood test to aid in the identification of approved test ovarian cancer in women diagnosed with an adnexal mass. w Exclusive r
Slide 23: Endometriosis: A Diagnostic Dilemma
Endometriosis: A Diagnostic Dilemma Endometriosis is a debilitating condition in which tissue similar to the lining of the uterus grows outside the uterus. It affects an estimated 6.5 million women in the U.S. alone. Only 50% of women who undergo a laparoscopic procedure are diagnosed with endometri
Slide 24: ENDOinform Protein + miRNAs-based Assay for Diagnosis of Endometriosis
“0ZENDOinform" Protein + miRNAs-based Assay for Diagnosis of Endometriosis Aspira’s Advantages Leverages OVAinform platform development wy Ongoing clinical study providing samples to complete development GB Experience in artificial intelligence/machine learning derived classification, algorithm enab
Slide 25: Strategic Focus on Evolving our Technology, Capabilities, and Collaborations
Strategic Focus on Evolving our Technology, Capabilities, and Collaborations We aspire to radically improve health outcomes for all people born with a female reproductive system through the development and commercializa in of advanced gynecologic disease diagnostic solutions OvaSuite Adoption and Gr
Slide 26: Contact Us
Aspira Women's Health — Investor Presentation (January 2025) on 6ix